Vaishali Pharma Ltd
NSE:VAISHALI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Vaishali Pharma Ltd
Income from Continuing Operations
Vaishali Pharma Ltd
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Vaishali Pharma Ltd
NSE:VAISHALI
|
Income from Continuing Operations
₹8.2m
|
CAGR 3-Years
-41%
|
CAGR 5-Years
90%
|
CAGR 10-Years
18%
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Income from Continuing Operations
₹55.2B
|
CAGR 3-Years
15%
|
CAGR 5-Years
16%
|
CAGR 10-Years
11%
|
|
|
Cipla Ltd
NSE:CIPLA
|
Income from Continuing Operations
₹45.4B
|
CAGR 3-Years
19%
|
CAGR 5-Years
15%
|
CAGR 10-Years
10%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Income from Continuing Operations
₹105.8B
|
CAGR 3-Years
35%
|
CAGR 5-Years
41%
|
CAGR 10-Years
7%
|
|
|
Lupin Ltd
NSE:LUPIN
|
Income from Continuing Operations
₹46.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
32%
|
CAGR 10-Years
8%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Income from Continuing Operations
₹22.7B
|
CAGR 3-Years
40%
|
CAGR 5-Years
14%
|
CAGR 10-Years
4%
|
|
Vaishali Pharma Ltd
Glance View
Vaishali Pharma Ltd. is a healthcare company, which engages in the marketing of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2017-08-22. The firm is engaged in dealing in pharmaceutical ingredient, pharmaceutical formulations, surgical products, herbal and nutraceutical products, veterinary supplements operating in domestic and export market. In domestic markets, it is engaged in contract manufacturing and trading of active pharmaceuticals ingredient's (APIs) and supply of API's for export captive consumption. In export markets, it is engaged in manufacturing and export of pharmaceutical formulations; manufacturing and export of surgical products; manufacturing and export of veterinary products; and manufacturing and export of herbal and nutraceuticals products. Its product categories include API, formulation brands, formulations, herbal, nutraceuticals, oncology, surgical and veterinary, among others. The firm markets approximately 400 products in domestic and APIs has a product portfolio of more than 1,000 products for the overseas market.
See Also
What is Vaishali Pharma Ltd's Income from Continuing Operations?
Income from Continuing Operations
8.2m
INR
Based on the financial report for Mar 31, 2025, Vaishali Pharma Ltd's Income from Continuing Operations amounts to 8.2m INR.
What is Vaishali Pharma Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
18%
Over the last year, the Income from Continuing Operations growth was 14%. The average annual Income from Continuing Operations growth rates for Vaishali Pharma Ltd have been -41% over the past three years , 90% over the past five years , and 18% over the past ten years .
